Improved cross-protection and immunity against influenza A virus in mice using a novel mRNA vaccine with optimized design of RNA sequence

T cell responses, and more effective protection than those of HNH-ORI, owing to their lower minimum free energy and higher codon adaptation index. These results reveal that the LPP-HNH mRNA vaccine encoding conserved antigens with optimized sequences is a promising strategy for the development of universal influenza vaccines.